Sia Daneshmand, MD

Sia Daneshmand, MD, is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer.

Articles by Sia Daneshmand, MD

Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | November 20, 2024
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
View More
Sia Daneshmand, MDUrothelial Carcinoma | November 20, 2024
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | August 26, 2024
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | August 26, 2024
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel shares predictions for the future of bladder cancer.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel discusses other exciting treatment advances in bladder cancer.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
How the potential shift of new therapies to the frontline setting will impact subsequent treatment decisions.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel shared their thoughts on the EV-302 study.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
Sam Chang, MDUromigos Live 2023 | November 6, 2023
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.